Contract development and manufacturing organisation ViroCell Biologics has partnered AvenCell Therapeutics for expediting the development of new allogeneic chimeric antigen receptor (CAR)-T therapies to treat blood cancers.
The company also announced the delivery of a new retroviral vector to AvenCell Therapeutics.
The initial vector will be utilised to produce AVC-203, an experimental cluster of differentiation 19 and 20 (CD19/CD20) dual-targeted cell therapy for B-cell malignancies and autoimmune diseases.
AvenCell’s AVC-203 represents its second investigational treatment using allogeneic engineering techniques to create an off-the-shelf product to prevent both graft-versus-host disease and rejection by the patient’s T cells and natural killer (NK) cells.
The therapy enables immediate treatment and broader patient access, as well as cutting costs.
The addition of AvenCell鈥檚 RevCAR receptor into AVC-203 further enhances its targeting beyond CD19 and CD20.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataViroCell CEO John Hadden II stated: 鈥淚 am proud of Team ViroCell鈥檚 accomplishments in the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need.
鈥淲e look forward to continuing our work with AvenCell on their exciting platform.鈥�
AvenCell鈥檚 collaboration with ViroCell was based on the company鈥檚 expertise in producing high-yield vectors quickly.
By incorporating a cell line from AvenCell into good manufacturing practice processes, ViroCell met the challenge of delivering a high-yield vector within the required timeframe.
This achievement demonstrates ViroCell’s capability to manage complex production demands in the field of allogeneic CAR T-cell therapies.
A first-in-human Phase I study involving patients with relapsed or refractory B-cell lymphoma is expected to commence using AVC-203 in the second half of 2025.
AvenCell CEO Andrew Schiermeier stated: 鈥淲e selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can鈥檛. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well-placed.鈥�
Cell & Gene Therapy coverage on 天美传媒app Technology is supported by听Cytiva.
Editorial听content is independently produced and follows the听听of journalistic integrity. Topic sponsors are not involved in the creation of听editorial听content.
